Cell Therapeutics lisofylline mucositis Phase II/III trial planned for 1997.
CTI LISOFYLLINE PHASE II/III MUCOSITIS TRIAL TO BEGIN IN SECOND HALF OF 1997, Cell Therapeutics reports in a prospectus for an initial public offering. The 100-patient mucositis study will compare a 3 mg/kg dose of CTI's synthetic small molecule drug four times daily to a 6 mg/kg twice daily dose in patients with solid tumors receiving dose-intensive radiation and/or chemotherapy who are at risk for developing severe mucositis and infection. Lisofylline appears to decrease the pool of oxidizable lipids following radiation or chemotherapy, CTI said, preventing related cellular inflammatory response.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth